Northern Cancer Institute Current List of Clinical Trials

Please refer to the list below for clinical trials which are currently recruiting at the Northern Cancer Institute, St Leonards. The list is continually being updated as recruitment closes and new trials commence. For enquiries about current or future trials please contact Iona Nicolson Bowles at

Study name and TitleStatus
Basket - All or Multiple Tumour Types
Tumor Bank Collection and Banking of Fresh Tumors for Frozen StorageOpen
Vaccine Activate A single centre, open label, first in human, phase 1 dose escalating study to evaluate the safety, tolerability and preliminary efficacy of an autologous cancer vaccine, rgsh4k, administered intradermally in patients with advanced cancers. Open
MK 3475-057 A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory or Intolerant to BCG Therapy. Open
Danube A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer Open
SOLAR-1 A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment Open
Strict Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial Open
Ascolt Aspirin for dukes c and high risk dukes b colorectal cancers. An international, multi centre, double blind, randomised placebo controlled phase III trial Open
Meso BI Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma Open
Bayer Meso A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtanisine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy Open
BMS - A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Open
BR31 A phase III prospective double blind placebo controlled randomized study of adjuvant Medi4736 in completely resected non-small cell lung cancer. Open
MesomIr A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced NSCLC failing on standard therapy Open
Abbvie Ovarian A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
Aramis Androgen Receptor inhibiting Agent for Metastatic-Free Survival in prostate cancer patients Open
Embark A Phase 3, randomized, efficacy and safety study of Enzalutamide plus Leuprolide, Enzalutamide monotherapy, and placebo plus Leuprolide in men with high-risk non-metastatic prostate cancer progressing after definitive therapy. Open
Enzamet First line androgen deprivation therapy for metastatic prostate cancer Open
Titan A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Open
BL12 A multicentre randomized phase ii trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen. Open